Reports Q1 revenue $22.1M, consensus $10.73M. “The Kymera team continues to advance our first-in-class pipeline on the path to revolutionizing the treatment of complex immuno-inflammatory diseases,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics (KYMR). “We are making tremendous progress across our programs and approaching key near term inflection points. In June, we will be sharing the KT-621 healthy volunteer data for our STAT6 program, an important milestone in the development of this franchise. Additionally, we recently initiated, well ahead of schedule, patient dosing in the KT-621 BroADen Phase 1b study, with data in the fourth quarter of this year. This is another important inflection point as we rapidly progress KT-621 toward later-stage studies.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- KYMR Upcoming Earnings Report: What to Expect?
- Kymera Therapeutics to unveil new oral development candidate
- Kymera Therapeutics announces first patient dosed in BROADEN Phase 1b trial
- Kymera Therapeutics appoints Goodman as Chief Business Officer
- Cautious Hold Rating on Kymera Therapeutics Amid Promising KT-621 Prospects and Strategic Developments
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue